CRSP

CRISPR Therapeuticsdistress 2/10 · well-funded / low risk

$46.62-1%today-39% from 52w high

crisprtx.comFounded 2013Zug, SwitzerlandBiotechnology

Oncology 2Metabolic / Obesity 1

Lead: Diabetes Mellitus · est. market ~$70B (approx, global)

Revenue

pre-revenue

Liquidity

$2442M

Runway

6.1 yrs

Shares 1y

+6%

Price & events

-23.3% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.3%

-4.0%

-13.7%

-15.5%

-16.0%

-31.6%

-18.5%

-61.9%

-70.5%

All

Overview

Market Cap: $4.50B
Enterprise Value: $4.66B
Volume: 414.97K
52 Week Range: $44.34 – $76.78
Total Shares: 96.45M
Float Shares: 96.04M
Short %: 23.65%
% Held by Insiders: 5.91%
% Held by Institutions: 79.34%
RVOL: 0.25x
Beta: 1.70

Pipeline stages · 3 programs

CTX112

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2030-01

CTX131

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

VCTX211

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 5 trials · 2 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2030-01 Estimated 50% readout ~2030-02-15	Phase 1/2	CTX112	B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Large B-cell Lymphoma	—	recruiting
2033-12 Estimated 50% readout ~2034-01-15	Phase 1/2	CTX112	Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura	—	recruiting
2026-03-11	Phase 1/2	CTX131	T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia	12	completed
2025-09-18	Phase 1/2	CTX131	Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma	19	completed
2025-08-08	Phase 1	VCTX211	Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases	5	terminated